177lu-dota-tlx591
mAbexperimentalADC
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT04786847)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
Chemistry & pharmacology
- Payload
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06549465 | Phase 2 | Aug 6, 2024 | Convergent Therapeutics, Inc. |
| NCT06520345 | Phase 3 | Jul 26, 2024 | Telix |
| NCT05146973 | Phase 2 | Jun 1, 2022 | Telix |
| NCT04876651 | Phase 3 | Mar 15, 2022 | Telix |
| NCT04786847 | Phase 1 | Nov 30, 2021 | Telix |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telix | For profit | 4 | 4 | 3 | 2021 |
| Convergent Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1